TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presented Fri 28 Aug · 11:15 CESTHot Line 1All Hot Line trials →

SINGLE-AF

2026

The Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Intermediate Stroke Risk in Patients With Atrial Fibrillation

In 1,803 patients with atrial fibrillation at intermediate stroke risk, a direct oral anticoagulant reduced the net composite of stroke, embolism, major bleeding and death at 2 years compared with no anticoagulation.

Result

Efficacy: Composite of stroke, systemic embolism, ISTH major bleeding and cardiovascular death at 2 yearsHR 0.31 (95% CI 0.10-0.94) · P = 0.03

Below 1 favours a direct oral anticoagulant, above 1 favours no anticoagulation.

Event rates
Absolute difference
1.0 points
NNT
100

Absolute difference and NNT are derived from the event rates.

Also reported: Driven by ischaemic stroke (0.1% vs 1.1%). Major bleeding 0.3% vs 0.5%.

Original publication
Subtopic
Stroke prevention
Design
Investigator-initiated, multicentre, open-label, superiority RCT with blinded outcome adjudication (PROBE), 1:1, permuted blocks stratified by centre, 24-month follow-up, South Korea
Relevance
Important: one of several pillars.
Source
Kim D, Lee Y, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607978

Discussion & critique

The first randomised answer for atrial fibrillation with a single stroke risk factor, and it favours anticoagulating. Fewer than 20 primary events across 1,803 patients carry the result: the interval runs to 0.94, so the direction is firmer than the size. Open-label at 18 Korean centres, with an observed event rate far below the planning assumption and an absolute difference of one percentage point.

Discussed in podcasts